sheff PIOI is one of my favorite risk/return ideas from this level. Mkt cap so low, yet NOLs so high. They are patiently working on their accretive acquisition. They need to get some creative financing in concert w/ the acq, but regardless it should be a nice catalyst. A wildcard is the patent portfolio, which i assign $0 value to until they monetize them, but that could be a nice catalyst at some point as well.
One other non-biotech OTC that I'd mention in terms of favorable r/r is STKR. They are profitable, .08, and are in a hot niche sector (3D scanning lasers). Some of their products are applicable to the AR/VR food chain.
Solid DD combined with timeliness and conviction is a recipe for profits.
